title: Induction immunosuppression for patients bridged to transplantation.
abstract: From January 1987 through July 1989, nine patients (eight male, one female) underwent bridge to transplantation and were managed with a modified immunosuppression regimen based around the monoclonal antibody OKT3. Six patients were bridged with the Jarvik-7 70 cc total artificial heart, four patients with centrifugal ventricular assist devices, and one patient with a Novacor left ventricular assist system. In two patients two devices were used. There was one patient death at 29 days after transplantation because of acute rejection. One other patient had a rejection episode 368 days after transplantation, for an overall rejection incidence of 0.22 episodes/patient. Four infections occurred, and all were viral--three cytomegalovirus and one mumps. Posttransplant complications involving other organ systems were minimal. In follow-up, from 2 to 29 months, six patients are in New York Heart Association functional status class I and one is in class II. Six patients are not taking steroids. The serum cholesterol level in the patients not receiving steroids at 6 and 12 months is 151 +/- 11 and 171 +/- 23 mg/dl (+/- SEM), respectively. Because of these results we have expanded our indications for the modified regimen using OKT3 in patients with preoperative organ system dysfunction, in diabetic patients, in pediatric patients, in female patients, and in posttransplant patients who require mechanical assistance.
authors.affiliation: Minneapolis Heart Institute/Abbott Northwestern Hospital, Minn.
authors.forename: R W
authors.initials: RW
authors.lastname: Emery
authors.forename: L D
authors.initials: LD
authors.lastname: Joyce
authors.forename: M R
authors.initials: MR
authors.lastname: Pritzker
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D016027:Heart Transplantation; D006354:Heart, Artificial; D006353:Heart-Assist Devices; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3; D011300:Preoperative Care; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3